FOXA1 and neoplasm: In endocrine-resistant breast cancer, FOXA1 is significantly amplified and enhances tumour aggressiveness by activating IL-8 signalling to further promote tumour invasion, metastasis and therapy resistance (Britschgi et al., 2012; Singh et al., 2013; Fu et al., 2016).